EDIT
Price
$2.58
Change
-$0.11 (-4.09%)
Updated
Jul 31 closing price
Capitalization
395.93M
2 days until earnings call
Intraday BUY SELL Signals
NKTX
Price
$2.09
Change
-$0.06 (-2.79%)
Updated
Jul 31 closing price
Capitalization
149.53M
3 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs NKTX

EDIT vs NKTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. NKTX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and NKTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (EDIT: $2.58 vs. NKTX: $2.09)
Brand notoriety: EDIT and NKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 33% vs. NKTX: 80%
Market capitalization -- EDIT: $395.93M vs. NKTX: $149.53M
EDIT [@Biotechnology] is valued at $395.93M. NKTX’s [@Biotechnology] market capitalization is $149.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileNKTX’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • NKTX’s FA Score: 1 green, 4 red.
According to our system of comparison, NKTX is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 2 TA indicator(s) are bullish while NKTX’s TA Score has 3 bullish TA indicator(s).

  • EDIT’s TA Score: 2 bullish, 7 bearish.
  • NKTX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, NKTX is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а -0.77% price change this week, while NKTX (@Biotechnology) price change was -7.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.

Reported Earning Dates

EDIT is expected to report earnings on Aug 05, 2026.

NKTX is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EDIT($396M) has a higher market cap than NKTX($150M). EDIT YTD gains are higher at: 25.854 vs. NKTX (12.973). EDIT has higher annual earnings (EBITDA): -100.08M vs. NKTX (-107.08M). NKTX has more cash in the bank: 230M vs. EDIT (124M). EDIT has less debt than NKTX: EDIT (17.3M) vs NKTX (75M). EDIT has higher revenues than NKTX: EDIT (38.7M) vs NKTX (0).
EDITNKTXEDIT / NKTX
Capitalization396M150M264%
EBITDA-100.08M-107.08M93%
Gain YTD25.85412.973199%
P/E RatioN/AN/A-
Revenue38.7M0-
Total Cash124M230M54%
Total Debt17.3M75M23%
FUNDAMENTALS RATINGS
EDIT vs NKTX: Fundamental Ratings
EDIT
NKTX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6079
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NKTX's Valuation (8) in the null industry is significantly better than the same rating for EDIT (86) in the Biotechnology industry. This means that NKTX’s stock grew significantly faster than EDIT’s over the last 12 months.

NKTX's Profit vs Risk Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that NKTX’s stock grew similarly to EDIT’s over the last 12 months.

NKTX's SMR Rating (98) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that NKTX’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (60) in the Biotechnology industry is in the same range as NKTX (79) in the null industry. This means that EDIT’s stock grew similarly to NKTX’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NKTX (100) in the null industry. This means that EDIT’s stock grew similarly to NKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITNKTX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
78%
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signal:
Gain/Loss:
NKTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JVAPX40.540.32
+0.80%
JPMorgan Value Advantage R3
RYHOX91.600.54
+0.59%
Rydex NASDAQ-100® H
TMCGX16.740.05
+0.30%
Thrivent Mid Cap Growth S
LGOVX36.31-0.11
-0.30%
Lord Abbett Growth Opportunities R6
SUHAX38.83-0.31
-0.79%
DWS Health and Wellness A

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRBU. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-4.09%
CRBU - EDIT
65%
Loosely correlated
-3.31%
BEAM - EDIT
63%
Loosely correlated
-3.66%
PRME - EDIT
61%
Loosely correlated
-3.31%
CRSP - EDIT
58%
Loosely correlated
-0.93%
VYGR - EDIT
56%
Loosely correlated
-3.19%
More

NKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with EDIT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTX
1D Price
Change %
NKTX100%
-2.79%
EDIT - NKTX
53%
Loosely correlated
-4.09%
RXRX - NKTX
49%
Loosely correlated
-1.32%
PRME - NKTX
48%
Loosely correlated
-3.31%
RCKT - NKTX
48%
Loosely correlated
-3.12%
VIR - NKTX
47%
Loosely correlated
-2.70%
More